Aeterna Zentaris X-PECT Stage 3 refractory advanced colorectal cancer trial fails to meet primary endpoint Aeterna Zentaris Inc. The trial involving 468 patients in 65 sites in the U.S was conducted by the Company’s North American licensee partner, Keryx Biopharmaceuticals, Inc. . Related StoriesViralytics enters into clinical trial collaboration agreement with MSDFDA grants accelerated authorization for Tagrisso to take care of sufferers with advanced NSCLCNew RNA check of blood platelets may be used to identify area of cancerJuergen Engel, Ph.D., Aeterna Zentaris President and CEO, commented, Although we are obviously very disappointed that the trial did not meet its principal endpoint, I’d like to thank those involved in this trial because of their dedicated work.This is especially notable because individuals entering the analysis experienced an FEV1 of approximately 70 percent of the predicted value and, despite background therapy, wouldn’t normally have been considered to have well-managed asthma according to standard criteria . Rapid, sustained improvements over the duration of the analysis were also observed in symptoms, beta-agonist make use of, and ACQ5 score. For the ACQ5 rating, the between-group difference in the differ from baseline was 0.73 points, which is higher than the 0.5-point change taken into consideration to be significant clinically.20 Notably, the improvement in the ACQ5 rating with dupilumab was accompanied by a noticable difference in the SNOT-22 total rating at week 12, but this difference did not reach the level regarded as clinically significant.